X
[{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$393.6 million","upfrontCash":"$8.5 million","newsHeadline":"OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"OSE Immunotherapeutics SA"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The collaboration grants Veloxis worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. OSE Immunotherapeutics retains all rights to develop FR104 in autoimmune diseases.
Lead Product(s):
FR104
Therapeutic Area: Immunology
Product Name: FR104
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Veloxis Pharmaceuticals
Deal Size: $393.6 million
Upfront Cash: $8.5 million
Deal Type: Collaboration
April 26, 2021
Details:
The patent covers novel dosing regimen of FR104 in Europe through 2036 for therapeutic applications in autoimmune diseases, inflammatory diseases, transplantation and graft-versus-host disease.
Lead Product(s):
FR104
Therapeutic Area: Immunology
Product Name: FR104
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 12, 2020